By Mrinalika Roy

(Reuters) -AstraZeneca and Daiichi Sankyo’s new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat forms of the disease.

Patients with triple-negative breast cancer who were given the drug, Datroway, had a median overall survival of 23.7 months, compared with 18.7 months for those given just chemotherapy. Patients on Datroway also had significantly better response to the drug and survival without progression of disease, the drug showed.

The companies presented the data at European Society for Medical Oncology Congress on Sunday.

“This is the first time we show survival superiority of a new approach like Datroway versus standard chemotherapy,” said Abder Laadem,

See Full Page